Interest of adding donepezil to the non-medicinal care pathway recommended in France for Alzheimer's disease: CHOLINE-2 study - CHOLINE-2

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 120 人开始时间: 2021年5月12日最近更新: 2024年7月15日

试验速览

暂无简介。

•- Diagnosis of Alzheimer's disease according to the 2014 IWG-2 criteria.
•- Covered by social security.
•- Age = 50 years old.
•- Lack of legal protection measure (guardianship, curatorship).
•- MMSE score = 10 on inclusion.
•- Aß42 in the CSF or abnormal Aß40 / Aß42 ratio according to the local cut-offs of the different centers.
•- Phosphorylated tau in the CSF abnormal according to the local cut-offs of the different centers.
•- Presence of a family companion or a person at home who can ensure compliance with treatment in the event of an MMSE score <20.
•- Sufficient command of the French language for the taking of neuropsychological tests.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 60

•- Another cause of major neurocognitive disorder.
•- Cardiological contraindication after possible opinion of a cardiologist, at the initiative of the investigator, in particular bradycardia, presence of 2nd or 3rd degree atrioventricular block.
•- Previous treatment of symptomatic Alzheimer's disease.
•- Participation in another intervention research

发起方